Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2a Study of PF-06873600 Alone and with Endocrine Therapy in Advanced Solid Tumors
jRCT2031230326Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2021
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of ebvaciclib in breast cancer, triple-negative breast cancer (TNBC), epithelial ovarian cancer (EOC) and 2 more (8 arms), sponsored by Pfizer. Primary endpoints: Number of patients with dose limiting toxicities in the Dose Escalation portion, Safety and Tolerability and 1 more. Started Sep 2021; status: completed.
02
Drugs
ebvaciclib
03
Conditions
breast cancertriple-negative breast cancer (TNBC)epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCT2031230326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230326.